Brief: Revive Therapeutics Provides Update On The Psilocybin Clinical Study For Methamphetamine Use Disorder And Oral Psilocybin Thin Film Strip Program
16/09/2022 11:01
Sept 16 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON THE PSILOCYBIN
CLINICAL
STUDY FOR METHAMPHETAMINE USE DISORDER AND ORAL PSILOCYBIN THIN
FILM STRIP PROGRAM
* REVIVE THERAPEUTICS LTD - EXPECTS TO CONDUCT A
FIRST-IN-HUMAN
CLINICAL STUDY IN 2023
Source text for Eikon: ID:nGNX5mS3tB
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure